D'Argenio DZ - Search Results

1

Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.

Hu S, D'Argenio DZ. Hu S, et al. J Pharmacokinet Pharmacodyn. 2020 Oct;47(5):385-409. doi: 10.1007/s10928-020-09691-3. Epub 2020 Jun 4. J Pharmacokinet Pharmacodyn. 2020. PMID: 32500362 Free PMC article.

2

Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties.

Hu S, Datta-Mannan A, D'Argenio DZ. Hu S, et al. Among authors: d argenio dz. MAbs. 2022 Jan-Dec;14(1):2056944. doi: 10.1080/19420862.2022.2056944. MAbs. 2022. PMID: 35491902 Free PMC article.

3

An Analysis of Glucose Effectiveness in Subjects With or Without Type 2 Diabetes via Hierarchical Modeling.

Hu S, Lu Y, Tura A, Pacini G, D'Argenio DZ. Hu S, et al. Among authors: d argenio dz. Front Endocrinol (Lausanne). 2021 Mar 29;12:641713. doi: 10.3389/fendo.2021.641713. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33854483 Free PMC article.

4

Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.

Xu L, Eiseman JL, Egorin MJ, D'Argenio DZ. Xu L, et al. J Pharmacokinet Pharmacodyn. 2003 Jun;30(3):185-219. doi: 10.1023/a:1025542026488. J Pharmacokinet Pharmacodyn. 2003. PMID: 14571691

5

Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab.

Kay BP, Hsu CP, Lu JF, Sun YN, Bai S, Xin Y, D'Argenio DZ. Kay BP, et al. J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):577-90. doi: 10.1007/s10928-012-9269-x. Epub 2012 Aug 30. J Pharmacokinet Pharmacodyn. 2012. PMID: 22932917 Free PMC article.

6

Feedback control indirect response models.

Zhang Y, D'Argenio DZ. Zhang Y, et al. J Pharmacokinet Pharmacodyn. 2016 Aug;43(4):343-58. doi: 10.1007/s10928-016-9479-8. Epub 2016 Jul 9. J Pharmacokinet Pharmacodyn. 2016. PMID: 27394724

7

FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.

Zhang Y, Hsu CP, Lu JF, Kuchimanchi M, Sun YN, Ma J, Xu G, Zhang Y, Xu Y, Weidner M, Huard J, D'Argenio DZ. Zhang Y, et al. J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):675-91. doi: 10.1007/s10928-014-9393-x. Epub 2014 Oct 19. J Pharmacokinet Pharmacodyn. 2014. PMID: 25326874 Free PMC article.

8

A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.

Chen W, Boras B, Sung T, Yu Y, Zheng J, Wang D, Hu W, Spilker ME, D'Argenio DZ. Chen W, et al. J Pharmacokinet Pharmacodyn. 2020 Apr;47(2):163-182. doi: 10.1007/s10928-020-09680-6. Epub 2020 Mar 11. J Pharmacokinet Pharmacodyn. 2020. PMID: 32162138 Free PMC article.

9

Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics.

D'Argenio DZ, Gastonguay MR, Brundage RC, Miller R, Tannenbaum SJ, Pfister M. D'Argenio DZ, et al. J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):3. doi: 10.1007/s10928-011-9237-x. J Pharmacokinet Pharmacodyn. 2012. PMID: 22219000 No abstract available.

10

A whole-body circulatory neutrophil model with application to predicting clinical neutropenia from in vitro studies.

Chen W, Boras B, Sung T, Hu W, Spilker ME, D'Argenio DZ. Chen W, et al. CPT Pharmacometrics Syst Pharmacol. 2021 Jul;10(7):671-683. doi: 10.1002/psp4.12620. Epub 2021 Jun 8. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33793091 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

84 results

Search Page

Filters